{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:16:16Z","timestamp":1771082176947,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2746-5","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T18:49:30Z","timestamp":1506710970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Muhammad","family":"Atif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arslan","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razia Kaneez","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehar","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"issue":"2","key":"2746_CR1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00079413","volume":"43","author":"R Diel","year":"2014","unstructured":"Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43(2):554\u201365.","journal-title":"Eur Respir J"},{"issue":"11","key":"2746_CR2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJMra0908076","volume":"363","author":"E Nathanson","year":"2010","unstructured":"Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, L\u00f6nnroth K, et al. MDR Tuberculosis \u2014 Critical Steps for Prevention and Control. N Engl J Med. 2010;363(11):1050\u20138.","journal-title":"N Engl J Med"},{"issue":"9","key":"2746_CR3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.5588\/ijtld.15.0167","volume":"19","author":"N Ahmad","year":"2015","unstructured":"Ahmad N, Javaid A, Basit A, Afridi AK, Khan MA, Ahmad I, et al. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19(9):1109\u201314. i-ii","journal-title":"Int J Tuberc Lung Dis."},{"issue":"6","key":"2746_CR4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1473-3099(13)70030-6","volume":"13","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529\u201339.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2746_CR5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018964","volume":"6","author":"WA Wells","year":"2011","unstructured":"Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One. 2011;6(5):e18964.","journal-title":"PLoS One"},{"key":"2746_CR6","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014. http:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en\/ . Accessed Sept 24 2017."},{"issue":"11","key":"2746_CR7","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.5588\/ijtld.10.0679","volume":"15","author":"F Qazi","year":"2011","unstructured":"Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, Salahuddin N, et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis. 2011;15(11):1556\u20139. i","journal-title":"Int J Tuberc Lung Dis."},{"issue":"4","key":"2746_CR8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093206","volume":"9","author":"A Basit","year":"2014","unstructured":"Basit A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, Afridi AK, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One. 2014;9(4):e93206.","journal-title":"PLoS One"},{"issue":"3","key":"2746_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","volume":"3","author":"EV Kurbatova","year":"2015","unstructured":"Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Res Med. 2015;3(3):201\u20139.","journal-title":"Lancet Res Med"},{"issue":"3","key":"2746_CR10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1378\/chest.117.3.744","volume":"117","author":"WW Yew","year":"2000","unstructured":"Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin\/levofloxacin-containing regimens. Chest. 2000;117(3):744\u201351.","journal-title":"Chest"},{"issue":"4","key":"2746_CR11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5588\/ijtld.12.0481","volume":"17","author":"M Rodriguez","year":"2013","unstructured":"Rodriguez M, Monedero I, Caminero JA, Encarnacion M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17(4):520\u20135.","journal-title":"Int J Tuberc Lung Dis."},{"key":"2746_CR12","doi-asserted-by":"crossref","unstructured":"Javaid A, Shaheen Z, Shafqat M, Khan AH, Ahmad N. Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. Am J Infect Control. 2016;45(2):190\u20133.","DOI":"10.1016\/j.ajic.2016.07.026"},{"key":"2746_CR13","unstructured":"World Health Organization. Global Tuberculosis Report 2016. 2016. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/ . Accessed 16 Nov 2016."},{"issue":"4","key":"2746_CR14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5588\/ijtld.15.0645","volume":"20","author":"S Tahseen","year":"2016","unstructured":"Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, et al. Use of Xpert((R)) MTB\/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int J Tuberc Lung Dis. 2016;20(4):448\u201355.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"2746_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5588\/ijtld.16.0444","volume":"21","author":"A Javaid","year":"2017","unstructured":"Javaid A, Hasan R, Zafar A, Chaudry M, Qayyum S, Qadeer E, et al. Pattern of first-and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan. Int J Tuberc Lung Dis. 2017;21(3):303\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2746_CR16","unstructured":"World Health Organization: Treatment of tuberculosis: guidelines: World Health Organization; 2010."},{"issue":"12","key":"2746_CR17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.15537\/smj.2015.12.12155","volume":"36","author":"MA Khan","year":"2015","unstructured":"Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar. Pakistan Saudi Med J. 2015;36(12):1463\u201371.","journal-title":"Pakistan Saudi Med J"},{"issue":"1","key":"2746_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3855\/jidc.1738","volume":"6","author":"M Khurram","year":"2012","unstructured":"Khurram M, Khaar HT, Fahim M. Multidrug-resistant tuberculosis in Rawalpindi. Pakistan J Infect Dev Ctries. 2012;6(1):29\u201332.","journal-title":"Pakistan J Infect Dev Ctries"},{"issue":"2","key":"2746_CR19","first-page":"94","volume":"21","author":"W Saeed","year":"2009","unstructured":"Saeed W, Naseem A, Ahmed J. Retrospective audit of patients treated for MDR-TB in re-treatment category. J Ayub Med Coll Abbottabad. 2009;21(2):94\u20138.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2746_CR20","unstructured":"Waheed Z, Irfan M, Haque AS, Khan MO, Zubairi A, ul Ain N, et al. Treatment Outcome of Multi-Drug Resistant Tuberculosis Treated As Outpatient in a Tertiary Care Center. Pak J Chest Med. 2011;17(3)."},{"issue":"3","key":"2746_CR21","doi-asserted-by":"crossref","first-page":"e0151321","DOI":"10.1371\/journal.pone.0151321","volume":"11","author":"M Atif","year":"2016","unstructured":"Atif M, Javaid S, Farooqui M, Sarwar MR. Rights and Responsibilities of Tuberculosis Patients, and the Global Fund: A Qualitative Study. PLoS One. 2016;11(3):e0151321.","journal-title":"PLoS One"},{"issue":"1","key":"2746_CR22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1186\/s40064-016-2716-1","volume":"5","author":"M Atif","year":"2016","unstructured":"Atif M, Bashir A, Saleem Q, Hussain R, Scahill S, Babar ZU. Health-related quality of life and depression among medical sales representatives in Pakistan. Spring. 2016;5(1):1048.","journal-title":"Spring"},{"key":"2746_CR23","unstructured":"National TB Program Pakistan. National guidelines for programmatic management of drug-resistant tuberculosis (PMDT). http:\/\/www.ntp.gov.pk\/uploads\/Programmatic_Management_of_Drug_resistant_Tuberculosis_PMDT.pdf .\u00a0Accessed Sept\u00a024 2017."},{"key":"2746_CR24","unstructured":"Pallant J: SPSS survival manual: McGraw-Hill Education (UK); 2013."},{"issue":"12","key":"2746_CR25","volume":"8","author":"S Tang","year":"2013","unstructured":"Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8(12):e82943.","journal-title":"PLoS One"},{"issue":"9","key":"2746_CR26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006914","volume":"4","author":"JC Johnston","year":"2009","unstructured":"Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914.","journal-title":"PLoS One"},{"issue":"11","key":"2746_CR27","volume":"2","author":"HS Cox","year":"2007","unstructured":"Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rusch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One. 2007;2(11):e1126.","journal-title":"PLoS One"},{"issue":"3","key":"2746_CR28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3201\/eid2203.151788","volume":"22","author":"TE Tupasi","year":"2016","unstructured":"Tupasi TE, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis. 2016;22(3):491\u2013502.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2746_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","volume":"9","author":"EW Orenstein","year":"2009","unstructured":"Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153\u201361.","journal-title":"Lancet Infect Dis"},{"key":"2746_CR30","unstructured":"Batyrshina Y, Petrenko T. Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation. Eur Resp J. 2014; 44(Suppl 58)."},{"issue":"1","key":"2746_CR31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1471-2334-14-333","volume":"14","author":"P Weiss","year":"2014","unstructured":"Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis. 2014;14(1):333.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"2746_CR32","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/588292","volume":"46","author":"MF Franke","year":"2008","unstructured":"Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844\u201351.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2746_CR33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","volume":"16","author":"M Zignol","year":"2016","unstructured":"Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185\u201392.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2746_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bjid.2015.09.011","volume":"20","author":"N Ahmad","year":"2016","unstructured":"Ahmad N, Javaid A, Sulaiman SA, Ming LC, Ahmad I, Khan AH. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis. 2016;20(1):41\u20137.","journal-title":"Braz J Infect Dis"},{"key":"2746_CR35","unstructured":"World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK390455\/ . Accessed 24 Sept 2017."},{"issue":"5","key":"2746_CR36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2746_CR37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","volume":"18","author":"K Aung","year":"2014","unstructured":"Aung K, Van Deun A, Declercq E, Sarker M, Das P, Hossain M, et al. Successful \u20189-month Bangladesh regimen\u2019for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180\u20137.","journal-title":"Int J Tuberc Lung Dis."},{"key":"2746_CR38","doi-asserted-by":"crossref","unstructured":"Javaid A, Ahmad N, Khan AH, Shaheen Z. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Resp J. 2016;49(1):1601967.","DOI":"10.1183\/13993003.01967-2016"},{"issue":"11","key":"2746_CR39","first-page":"1047","volume":"3","author":"FM Salaniponi","year":"1999","unstructured":"Salaniponi FM, Christensen JJ, Gausi F, Kwanjana JJ, Harries AD. Sputum smear status at two months and subsequent treatment outcome in new patients with smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 1999;3(11):1047\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"2746_CR40","first-page":"58","volume":"7","author":"R Singla","year":"2003","unstructured":"Singla R, Osman M, Khan N, Al-Sharif N, Al-Sayegh M, Shaikh M. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. India Int J Tuberc Lung Dis. 2003;7(1):58\u201364.","journal-title":"India Int J Tuberc Lung Dis"},{"key":"2746_CR41","doi-asserted-by":"crossref","unstructured":"Peng Lu, Qiao Liu, Leonardo Martinez, Haitao Yang, Wei Lu, Xiaoyan Ding et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J. 2017;49(3):1601558","DOI":"10.1183\/13993003.01558-2016"},{"issue":"1","key":"2746_CR42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4102\/sajhivmed.v12i1.214","volume":"12","author":"C Kenyon","year":"2011","unstructured":"Kenyon C, Wearne N, Burton R, Meintjes G. The Risks of Concurrent Treatment with Tenofovir and Aminoglycosides in Patients with Hiv-Associated Tuberculosis. South Afr J HIV Med. 2011;12(1):43\u20135.","journal-title":"South Afr J HIV Med"},{"issue":"5","key":"2746_CR43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2746_CR44","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/cid\/ciu619","volume":"59","author":"ML Bastos","year":"2014","unstructured":"Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014;59(10):1364\u201374.","journal-title":"Clin Infect Dis"},{"key":"2746_CR45","doi-asserted-by":"crossref","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Resp J. 2012:erj01347\u201302012.","DOI":"10.1183\/09031936.00134712"},{"issue":"6","key":"2746_CR46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3201\/eid2106.141907","volume":"21","author":"SE Smith","year":"2015","unstructured":"Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, et al. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis. 2015;21(6):1002\u201311.","journal-title":"Emerg Infect Dis"},{"key":"2746_CR47","doi-asserted-by":"publisher","unstructured":"Ahmad N, Javaid A, Syed Sulaiman SA, Afridi AK, Zainab, Khan AH. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients. Am J Ther. 2016. doi: 10.1097\/MJT.0000000000000421 .","DOI":"10.1097\/MJT.0000000000000421"},{"issue":"7","key":"2746_CR48","first-page":"648","volume":"5","author":"J Furin","year":"2001","unstructured":"Furin J, Mitnick C, Shin S, Bayona J, Becerra M, Singler J, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5(7):648\u201355.","journal-title":"Int J Tuberc Lung Dis."},{"key":"2746_CR49","doi-asserted-by":"crossref","unstructured":"Atif M, Ahmad M, Saleem Q, Curley L, Qamar-uz-Zaman M: Pharmaceutical Policy in Pakistan. In: Pharmaceutical Policy in Countries with Developing Healthcare Systems. edn.: Springer; 2017: p. 25\u201344.","DOI":"10.1007\/978-3-319-51673-8_3"},{"issue":"6","key":"2746_CR50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.5588\/ijtld.11.0635","volume":"16","author":"R Zachariah","year":"2012","unstructured":"Zachariah R, Harries AD, Srinath S, Ram S, Viney K, Singogo E, et al. Language in tuberculosis services: can we change to patient-centred terminology and stop the paradigm of blaming the patients? Int J Tuberc Lung Dis. 2012;16(6):714\u20137.","journal-title":"Int J Tuberc Lung Dis."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2746-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T03:29:12Z","timestamp":1570159752000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2746-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2746-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"article-number":"655"}}